ERBB2 and neoplasm: Specific tumor cells may also alter their intracellular signaling pathways in response to T-cell-redirecting therapy, as one study showed that disrupted interferon-gamma signaling in HER2-positive tumor cells conferred resistance to killing by BiTE/CAR-redirected T cells [18].